Influenza vaccine Oculorespiratory syndrome incidence is reduced in HIV

被引：1
|
作者：
Cooper, Curtis [1 ]
Thorne, Anona [2 ]
机构：
[1] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON K1H 8L6, Canada
[2] Canadian HIV Trials Network, Vancouver, BC, Canada
来源：
VACCINE | 2011年 / 29卷 / 45期
关键词：
HIV; Influenza; Vaccine; Oculorespiratory Syndrome; OCS;
D O I：
10.1016/j.vaccine.2011.08.066
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Clinical experience suggests Oculorespiratory Syndrome (ORS) following influenza vaccination is rare in HIV but this is not well evaluated. We assessed ORS incidence in a randomized influenza vaccine trial of HIV participants. The overall incidence was 0.8% suggesting that influenza vaccine ORS incidence is reduced in HIV. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：7876 / 7877
页数：2
相关论文
共 50 条
  • [21] High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine
    Yam, Karen K.
    Gipson, Erica
    Klein, Marina
    Walmsley, Sharon
    Haase, David
    Halperin, Scott
    Scheifele, David
    Ward, Brian J.
    Cooper, Curtis
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 655 - 662
  • [22] Elevated Inflammatory Mediators in Adults with Oculorespiratory Syndrome following Influenza Immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study
    Al-Dabbagh, Mona
    Lapphra, Keswadee
    Scheifele, David W.
    Halperin, Scott A.
    Langley, Joanne M.
    Cho, Patricia
    Kollmann, Tobias R.
    Li, Yan
    De Serres, Gaston
    Fortuno, Edgardo S., III
    Bettinger, Julie A.
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (08) : 1108 - 1114
  • [23] Role of incidence function in vaccine-induced backward bifurcation in some HIV models
    Sharomi, O.
    Podder, C. N.
    Gumel, A. B.
    Elbasha, E. H.
    Watmough, James
    MATHEMATICAL BIOSCIENCES, 2007, 210 (02) : 436 - 463
  • [24] Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial
    Zolla-Pazner, Susan
    Gilbert, Peter B.
    JOURNAL OF VIROLOGY, 2019, 93 (17)
  • [25] Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study
    Hansen, John
    Goddard, Kristin
    Timbol, Julius
    Zhang, Lea
    Lewis, Ned
    Dunkle, Lisa
    Izikson, Ruvim
    Klein, Nicola P.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
  • [26] Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients
    Tremblay, Cecile L.
    Rouleau, Danielle
    Fortin, Claude
    Toma, Emil
    Sylla, Mohamed
    Cyr, Lise
    Cote, Serge
    Baz, Mariana
    Sampalis, John
    Trautman, Lydie
    Sekaly, Rafick-Pierre
    Boivin, Guy
    VACCINE, 2011, 29 (07) : 1359 - 1363
  • [27] A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers
    Nilofar Massoudi
    Babak Mohit
    Journal of Clinical Immunology, 2021, 41 : 324 - 334
  • [28] Fluarix quadrivalent vaccine for influenza
    de Graaf, Hans
    Faust, Saul N.
    EXPERT REVIEW OF VACCINES, 2015, 14 (08) : 1055 - 1063
  • [29] Aflunov®: a prepandemic influenza vaccine
    Gasparini, Roberto
    Amicizia, Daniela
    Lai, Piero Luigi
    Panatto, Donatella
    EXPERT REVIEW OF VACCINES, 2012, 11 (02) : 145 - 157
  • [30] Parental acceptance of an intranasal vaccine: Example of influenza vaccine
    Marien, A-G
    Hochart, A.
    Lagree, M.
    Diallo, D.
    Martinot, A.
    Dubos, F.
    ARCHIVES DE PEDIATRIE, 2019, 26 (02): : 71 - 74
12345